Comparison of surgical modalities in the treatment of Merkel Cell Carcinoma
1. Mohs micrographic surgery was associated with significantly higher survival rates for patients with T1/T2 Merkel cell carcinoma with pathologically...
Dermatology
Nemolizumab Therapy for Moderate-to-Severe Prurigo Nodularis
1. Nemolizumab may reduce inflammatory, neural, and epithelial signalling in patients with prurigo nodularis by inhibiting IL-31. 2. Nemolizumab may...
Mental health disorders more prevalent amongst adults with inflammatory skin conditions
1. Anxiety and depression were more prevalent among individuals with eczema or psoriasis, and those with these inflammatory conditions were...
Dupilumab For Management of Bullous Pemphigoids
1. Dupilumab treatment for bullous pemphigoids resulted in improved clinical symptoms. 2. Patients with anti-BP180 antibody levels of at least...
High-risk patent foramen ovale increases the risk of decompression illness in divers
1. In this prospective cohort study, there was an increased incidence of physician-confirmed decompression illness (DCI) in divers with high-risk...
Organ Transplant-Associated Immunosuppression and Cutaneous Squamous Cell Carcinoma Outcomes
1. In this Norwegian study, patients receiving organ transplants with cutaneous squamous cell carcinoma (cSCC) had higher rates of developing...
Patient Perspective of Opioid Pain-Control Use After Mohs Micrographic Surgery
1. A theoretical risk of opioid addiction following surgery may affect patients’ choice of pain medications and thus, it is...
Identifying Culprit Drugs in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
1. Physicians are more likely to over-label patients as allergic to non-culprit drugs, in comparison to missing possible culprit drugs...
Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea
1. In this case series, ruxolitinib was associated with improved inflammatory markers in patients with disabling pansclerotic morphea (DPM). 2....
Upadacitinib is safe and effective in adolescents with moderate-to-severe atopic dermatitis
1. Upadacitinib, a new once-daily oral systemic medication, reduces eczema severity and improves clinician- and patient-reported measures in adolescents with...